Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis? 2020

Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
University Medical Center Utrecht, Clinical Pharmacy, Utrecht.

In the era of multiple daily dosing of systemic aminoglycosides, a circadian rhythm in the clearance of these vital antibiotics has been demonstrated in animals and healthy volunteers. Over the past decade, once-daily dosing regimens have been proved to be less nephrotoxic and were therefore adopted worldwide for most indications requiring treatment with an aminoglycoside. In this study, the effect of the time of administration on the pharmacokinetics of once-daily tobramycin in adults with cystic fibrosis (CF) experiencing a pulmonary exacerbation was investigated. In this open randomized study, patients with CF received intravenous tobramycin at 8:00 or 22:00 hours. Pharmacokinetic and kidney function parameters were compared between the 2 groups. Twenty-five patients were included. The mean weight-corrected clearances of tobramycin were 1.46 versus 1.43 mL/h*kg (P = 0.50) and mean volumes of distribution were 0.25 versus 0.27 L/kg (P = 0.54) for the 8:00 and 22:00 groups, respectively. In addition, no significant differences were detected in changes in estimated clearances of creatinine or tobramycin on day 1 and day 8 in the 8:00 or 22:00 group, indicating that there was no decline in clearance over time. At day 8 of therapy, the increase in serum blood urea nitrogen in the 22:00 group was significantly higher than that in the 8:00 group (1.8 versus 0.2 mmol/L, P = 0.015). The time of administration (8:00 versus 22:00) did not affect tobramycin pharmacokinetics in the adult CF population studied. The increase in serum blood urea nitrogen in the 22:00 group requires further investigation.

UI MeSH Term Description Entries
D008297 Male Males
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin
D061605 Administration, Intravenous Delivery of substances through VENIPUNCTURE into the VEINS. Intravenous Administration,Administrations, Intravenous,Intravenous Administrations

Related Publications

Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
April 2000, Antimicrobial agents and chemotherapy,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
May 1996, The Journal of antimicrobial chemotherapy,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
September 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
May 2002, Pediatric pulmonology,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
July 1998, The Journal of antimicrobial chemotherapy,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
November 1997, Chest,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
February 1999, Archives of disease in childhood,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
June 1998, Archives of disease in childhood,
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
August 2016, Journal of chemotherapy (Florence, Italy),
Erik M van Maarseveen, and Renske van der Meer, and Cees Neef, and Harry G M Heijerman, and Daniel J Touw
February 2002, The European respiratory journal,
Copied contents to your clipboard!